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The	retinoblastoma	tumor	suppressor	(RB)	protein	is	functionally	inactivated	in	the	majority	of	human	can-
cers	and	is	aberrant	in	one-third	of	all	breast	cancers.	RB	regulates	G1/S-phase	cell-cycle	progression	and	is	
a	critical	mediator	of	antiproliferative	signaling.	Here	the	specific	impact	of	RB	deficiency	on	E2F-regulated	
gene	expression,	tumorigenic	proliferation,	and	the	response	to	2	distinct	lines	of	therapy	was	investigated	in	
breast	cancer	cells.	RB	knockdown	resulted	in	RB/E2F	target	gene	deregulation	and	accelerated	tumorigenic	
proliferation,	thereby	demonstrating	that	even	in	the	context	of	a	complex	tumor	cell	genome,	RB	status	exerts	
significant	control	over	proliferation.	Furthermore,	the	RB	deficiency	compromised	the	short-term	cell-cycle	
inhibition	following	cisplatin,	ionizing	radiation,	and	antiestrogen	therapy.	In	the	context	of	DNA-damaging	
agents,	this	bypass	resulted	in	increased	sensitivity	to	these	agents	in	cell	culture	and	xenograft	models.	In	
contrast,	the	bypass	of	antiestrogen	signaling	resulted	in	continued	proliferation	and	xenograft	tumor	growth	
in	the	presence	of	tamoxifen.	These	effects	of	aberrations	in	RB	function	were	recapitulated	by	ectopic	E2F	
expression,	indicating	that	control	of	downstream	target	genes	was	an	important	determinant	of	the	observed	
responses.	Specific	analyses	of	an	RB	gene	expression	signature	in	60	human	patients	indicated	that	deregula-
tion	of	this	pathway	was	associated	with	early	recurrence	following	tamoxifen	monotherapy.	Thus,	because	
the	RB	pathway	is	a	critical	determinant	of	tumorigenic	proliferation	and	differential	therapeutic	response,	it	
may	represent	a	critical	basis	for	directing	therapy	in	the	treatment	of	breast	cancer.
Introduction
Breast cancer is the leading noncutaneous cancer diagnosis in 
American women, affecting more than 240,000 new patients per 
year. Treatment options for breast cancer are governed by the 
estrogen dependence of the tumor cells. Two-thirds of all breast 
cancers are estrogen receptor (ER) positive, and in these tumors 
ER serves as a molecular target for hormone ablation therapy 
(1). Antiestrogens, such as the widely used tamoxifen (Tam), are 
the first-line therapy for ER-positive tumors and efficiently elicit 
a G0/G1-phase arrest in hormone-dependent cancer cells (2, 3). 
This class of drugs is initially effective in curbing the growth 
of ER-positive tumors; however, many patients whose tumors 
initially respond to antiestrogen treatment develop cellular 
resistance to Tam while maintaining ER-positive disease (4–6). 
This suggests that genetic lesions downstream of ER bypass the 
effectiveness of therapy. Second-line therapies for tumors that 
exhibit resistance to antiestrogens have traditionally included 
radiation and chemotherapies that function by damaging 
DNA (e.g., cisplatin). Importantly, the critical determinants for 
therapeutic response to either antiestrogens or DNA-damaging 
agents are largely unknown.
The retinoblastoma tumor suppressor (RB) plays a central role 
in cell-cycle control and regulates the cellular response to diverse 
therapeutic agents. In quiescent cells, RB is hypophosphorylated 
and assembles transcriptional repressor complexes on the pro-
moters of E2F-regulated genes to block cell-cycle progression. In 
response to mitogenic factors, including estrogen in breast cancer 
cells, RB is inactivated through hyperphosphorylation catalyzed 
by the cyclin D–cyclin-dependent kinase 4 (cyclin D–cdk4) and 
cyclin E–cdk2 complexes (7–9). These modifications are sufficient 
to disrupt the interaction of RB with E2F proteins, thereby reliev-
ing transcriptional repression and permitting cell-cycle progres-
sion. In contrast, antimitogenic factors activate RB, inhibiting 
cell-cycle progression. For example, RB activity is instrumental in 
the DNA damage–induced cell-cycle checkpoint and is necessary 
for G1- and S-phase arrest following DNA-damaging events. Cor-
respondingly, Tam and other antiestrogens function to block RB 
phosphorylation and engage RB-mediated transcriptional repres-
sion of E2F (2, 3, 10, 11).
RB has been reported to be aberrant in approximately 20%–35% 
of breast cancers (12, 13) and has been associated with poor disease 
outcome. Additionally, loss of heterozygosity or other alterations 
at the Rb locus are routinely observed in primary breast cancer 
specimens (14–16). Furthermore, the overproduction of cyclin D1 
and cyclin E, which mediate the inactivation of RB, are relatively 
common events in breast cancer (17). Last, microarray analyses 
have indicated that deregulation of E2F target genes can be associ-
ated with poor prognosis in a select subset of breast cancer cases 
(18). The basis for these effects on breast cancer remains largely 
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unknown and has not been explicitly investigated with respect to 
breast cancer therapies. In this regard, there is clear evidence for 
context-dependent effects of RB, which could have implications 
for the therapeutic strategies employed.
Resistance to conventional therapy is one of the main causes of 
patient death associated with breast cancer. Given the frequent dis-
ruption of RB function in breast cancer, an 
understanding of the effect of this event 
upon the response to therapeutic agents is 
necessary for the optimal design of treat-
ment strategies. Here, we show that RB 
knockdown in breast cancer cells resulted 
in deregulation of E2F-regulated genes 
and a growth advantage in vitro, which was 
recapitulated by accelerated tumor devel-
opment in xenograft models. The effect 
of RB knockdown was determined in the 
context of radiation, cisplatin (cis-diam-
minedichloroplatinum II [CDDP]), or 
hormone ablation therapy. RB deficiency 
enabled cells to inappropriately progress 
through the cell cycle following challenge 
with all therapeutic modalities tested. In 
the context of DNA-damaging therapeu-
tics, RB deficiency increased therapeutic 
sensitivity in both cell culture and xeno-
graft models. In contrast, following Tam 
therapy, the bypass of cell-cycle inhibition 
enabled proliferation in the presence of 
therapy and corresponding therapeutic 
failure in xenograft models. Like RB deficiency, ectopic expres-
sion of E2F3 bypassed the cell-cycle arrest mediated by therapeu-
tic agents, suggesting that deregulated E2F activity underlies the 
changes in therapeutic response in RB-deficient breast cancer cells. 
Using a signature of 59 RB-regulated genes to probe microarray 
data from breast cancer patients treated with Tam, we revealed 
Figure 1
Efficient RB knockdown in breast cancer 
cells causes deregulation of RB/E2F target 
genes and increased proliferation kinetics. 
(A) MCF7 cells transfected with MSCV donor 
or MSCV siRb plasmids were selected with 
puromycin to isolate stable clones. Clones 
were screened by RB immunofluorescence 
as shown for MCF7 donor 1 and siRb28. 
Images were captured at equal exposures. 
Original magnification, ×20. (B) Lysates 
from MCF7 donor 1 and siRb28 clones 
were immunoblotted for expression levels 
of RB, PCNA, MCM7, cyclin E, cyclin A, 
cyclin D1, and p16INK4a. Cdk4 served as 
a loading control. (C) Cells represented in A 
were BrdU labeled for 10 hours, and BrdU 
immunofluorescence was performed and 
scored. (D) Cells represented in A were 
seeded at 3 × 105, cell growth assays were 
carried out for 9 days, and cells were counted 
every 3 days. (E) Lysates represented in B 
along with lysates from polyclonal popula-
tions of T47D and Zr-75-1 cells infected with 
retrovirus encoding donor or siRb88 plasmids 
were immunoblotted for expression levels of 
RB and cyclin D1. Lamin B served as a load-
ing control. (F) Retrovirally infected T47D and 
Zr-75-1 cells represented in E were seeded 
at 3 × 105, and growth assays were carried 
out as described for D.
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that highly elevated gene expression levels correlated with failure 
of Tam therapy. Together, these results demonstrate that aber-
rations in RB facilitate accelerated tumorigenic proliferation of 
breast cancer cells and differential response to 2 major breast can-
cer treatment modalities.
Results
Efficient RB knockdown confers increased growth kinetics. To investi-
gate the influence of RB function in breast cancer, we targeted 
its expression in the ER-positive and estrogen-dependent breast 
cancer cell line MCF7. Specific and stable knockdown of RB was 
achieved using a vector encoding short hairpin RNA (shRNA) 
directed against Rb. Multiple independent clones transfected 
with either the shRNA against Rb or vector control were isolated 
(Supplemental Figure 1; supplemental material available online 
with this article; doi:10.1172/JCI28803DS1). RB protein levels 
were determined using immunofluorescence and immunoblotting 
for RB (Figure 1, A and B, top panel). These results demonstrated 
that RB protein levels had been reduced to virtually undetectable 
levels, and hence the cells were considered RB deficient. Since it 
has been postulated that nearly all cancer cells harbor compro-
mised RB function, we initially determined the consequence of 
RB deficiency on E2F target gene expression. Thus, levels of the 
well-documented RB/E2F targets proliferating cell nuclear anti-
gen (PCNA), minichromosome maintenance 7 (MCM7), cyclin E, 
and cyclin A were evaluated by immunoblotting. The expression 
levels of all of these proteins were increased in the absence of RB. 
However, the levels of cyclin D1 and p16INK4a (reported to be 
lost in MCF7 cells; ref. 19) were not affected by the reduction in 
RB protein levels (Figure 1B). Analyses of cell-cycle progression by 
BrdU incorporation (Figure 1C, data from multiple clones are pre-
sented in Supplemental Figure 2) or cellular proliferation (Figure 
1D) demonstrated that knockdown of RB resulted in enhanced 
proliferation. To determine the role of RB in the growth kinetics 
of additional estrogen-dependent breast cancer cell lines, RB-pro-
ficient and -deficient polyclonal pools of both T47D and Zr-75-1 
cells were established by infection with retroviruses encoding 
either an shRNA directed against Rb or control plasmid. RB pro-
tein levels were diminished in these cell lines to a level comparable 
to those evident in the clonal MCF cells transfected with shRNA 
directed against RB (MCF7siRb28 cells), as determined by immu-
noblotting. As in MCF7 cells, cyclin D1 levels were unaffected by 
RB deficiency in T47D and Zr-75-1 cells (Figure 1E). Importantly, 
RB knockdown also conferred increased growth kinetics in these 
cell lines (Figure 1F). Thus, attenuation of RB alters the prolifera-
tive kinetics of established breast cancer cells.
To investigate the biological consequence of RB inactivation in 
tumorigenesis, we utilized nude mouse xenografts. RB-proficient 
and -deficient MCF7 cells (2 × 106) were injected contralaterally 
into the flanks of nude mice implanted with estrogen pellets to 
support tumor growth. RB-knockdown cells produced measur-
able tumors earlier than the controls and continued to grow with 
faster kinetics (Figure 2A), so that by 30 days the RB-knockdown 
tumors had grown to more than double the size of the control 
tumors. At this time, mice were injected with BrdU and euthanized. 
Tumors were excised and weighed (Figure 2B), confirming their 
larger size. Additionally, BrdU immunohistochemistry demon-
strated that the proliferative index was significantly higher in the 
RB-deficient tumors (Figure 2C). Thus, even in the context of an 
established breast cancer cell line, RB plays a pivotal role in modu-
lating tumorigenic proliferation.
Abrogation of the DNA damage checkpoint in RB-knockdown cells causes 
increased sensitivity. The RB and p53 tumor suppressors are known 
to be critical for induction of DNA damage checkpoints, and thera-
pies inducing DNA damage are used as an additional line of treat-
ment for ER-positive breast cancers resistant to hormonal therapy. 
Therefore, we investigated the role of these tumor suppressors in 
the response to therapeutic doses of DNA-damaging agents. Wild-
type MCF7, T47D, and Zr-75-1 cells were treated with 0, 8, or 16 μM 
CDDP and labeled with BrdU to determine the effect of the agent 
Figure 2
Tumor growth in nude mouse xenografts is accelerated 
in RB-knockdown cells. (A) MCF7 donor 1 or siRb28 
cells were harvested and resuspended in 3:1 PBS/
Matrigel mixture. Cells (2 × 106) in 150 μl of mixture 
were injected subcutaneously in a contralateral man-
ner in flanks of ovariectomized nude mice. Mice were 
implanted with E2 pellets, and tumors were measured 
every 4 days. (B) Excised tumors were weighed 30 
days after implantation. Tumor weights were plotted, 
and a 2-tailed Student’s t test assuming unequal vari-
ances was used to determine significance. Below: rela-
tive tumor size after excision 30 days following implan-
tation. Scale bar: 1 cm. (C) Nude mice represented 
in A were injected with BrdU 1 hour prior to sacrifice. 
Sectioned tumors were immunohistochemically stained 
and scored for BrdU incorporation, and statistical analy-
ses were carried out as described for B.
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on cell-cycle progression. Although these RB-positive cell types dif-
fer in p53 status, all cell lines exhibited a dose-dependent cell-cycle 
checkpoint in response to CDDP treatment (Figure 3A). To spe-
cifically probe the impact of RB in the response to DNA damage, 
T47D and Zr-75-1 polyclonal siRb88 cells were utilized, with donor 
cells as controls. These studies demonstrated that RB-proficient 
T47D and Zr-75-1 cells initiated a dose-dependent checkpoint after 
CDDP treatment, whereas RB-deficient cells continued to incorpo-
rate BrdU efficiently following DNA damage (Figure 3B). To con-
firm these findings, MCF7 donor 1 and siRb28 cells were treated 
either with CDDP as described above or with 0, 2.5, or 5 Gy ionizing 
radiation (IR). Similarly, these studies revealed that RB deficiency 
promoted bypass of the DNA damage checkpoints induced by both 
CDDP and IR treatment in MCF7 cells (Figure 3C). To determine 
the long-term effect of DNA damage therapy upon proliferation, 
cell growth assays were performed wherein the RB-proficient and 
-deficient MCF7 clones were plated at equal density and treated 
with 2.5 or 5 Gy IR. Cell counting over 12 days revealed that the 
Figure 3
RB deficiency enables bypass of the DNA damage checkpoint, resulting in increased sensitivity. (A) Wild-type MCF7, T47D, and Zr-75-1 cells 
were treated with 0, 8, or 16 μM CDDP for 18 hours, washed, and labeled with BrdU for 10 hours in culture. Cells were then fixed, and BrdU 
immunofluorescence was performed and scored. (B) Retrovirally infected T47D (left) and Zr-75-1 (right) donor and siRb88 cells were treated 
with 0, 8, or 16 μM CDDP and BrdU labeled as described for A. (C) MCF7 donor 1 and siRb28 clones were treated with 0, 8, or 16 μM CDDP for 
18 hours prior to washing (left) or with 0, 2.5, or 5 Gy IR (right) and BrdU labeled as described above. (D) MCF7 donor 1 or siRb28 cells were 
seeded at 3 × 105 and treated with 2.5 (left) or 5 Gy IR (right), and cell growth assays were performed for 12 days and cells counted every 3 
days. (E) Harvested MCF7 donor 1 and siRb28 cells were resuspended 3:1 in PBS/Matrigel and injected subcutaneously into the flanks of mice 
implanted with E2 pellets. When xenograft tumors reached approximately 110 mm3 during tumor development, mice were treated with CDDP (the 
E2 pellet was retained, and 5 mg/kg CDDP was injected i.p. every 4 days for 5 courses), and tumor size was monitored by caliper measurement. 
Tumor measurements are plotted, and a 2-tailed Student’s t test assuming unequal variances was used to determine significance of curves. (F) 
Tumors represented in E were weighed upon excision.
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RB-knockdown cells were more sensitive to IR following treatment 
with 2.5 and 5 Gy Ir relative to the donor control cells (Figure 3D). 
These data demonstrate that the ability of the RB-knockdown cells 
to progress through the cell cycle in the presence of DNA damage 
was associated with increased sensitivity to these agents.
Further studies of p53 function were carried out in the MCF7 
RB-proficient and -deficient clones infected with either empty ret-
roviral vector, LXSN, or LXSN-p53dd, an N-terminally truncated, 
dominant-negative form of murine p53. Consistent with previ-
ously published results, immunoblots revealed an accumulation 
of p53 evident in LXSN-p53dd–infected cells as compared with 
controls; however, these elevated levels were not associated with an 
increase in p21 following exposure to 16 μM CDDP for 18 hours, 
suggesting that p53 function had been effectively compromised 
(20, 21) (Supplemental Figure 4A). These studies revealed that 
p53 dysfunction does not impact normal cell proliferation, but 
it does compromise the DNA damage checkpoint similarly to RB 
deficiency (Supplemental Figure 4, B and C). Additionally, p53 
function did not significantly affect the long-term sensitivity to 
DNA damage imparted by IR, suggesting that RB is a more critical 
determinant of the therapeutic response to these types of therapies 
in this context (Supplemental Figure 4D).
The xenograft model system was then utilized to test the response 
of RB-deficient tumors to CDDP therapy. Tumors were developed 
in the flanks of mice by injecting MCF7 donor or siRb cells into the 
flanks of mice and implanting a 17β-estradiol (E2) pellet into the 
back. When tumors reached 100–110 mm3, mice received 5 mg/kg 
CDDP every 4 days for 5 courses. These experiments revealed that 
both tumor types regressed during CDDP treatment; however, 
the RB-deficient tumors regressed more rapidly throughout the 5 
courses of therapy (Figure 3E) and failed to demonstrate any recov-
ery following the completion of therapy. Upon excision, all tumors 
were weighed, and the results demonstrate that tumors lacking RB 
function weighed less than half as much as control tumors follow-
ing CDDP therapy (Figure 3F), indicating that RB-deficient tumors 
respond more favorably to DNA damage therapy.
RB-deficient cells are able to bypass estrogen ablation therapy. To deter-
mine the effect of first-line breast cancer antiestrogen therapies on 
RB function, cells were exposed to several therapeutically relevant 
conditions. Specifically, wild-type MCF7, T47D, and Zr-75-1 cells 
were cultured in medium containing either FBS or charcoal dex-
tran–treated (CDT) serum in addition to Tam, so as to antagonize 
ER function. In all cell lines, cyclin D1 levels decreased following 
72 hours of hormone deprivation, yielding RB dephosphorylation 
despite undetectable levels of p16INK4a. U2OS and SaOS2 cells 
were included as controls for RB and p16INK4a expression levels, 
respectively (Figure 4A). To understand the impact of RB defi-
ciency on the response to hormone deprivation therapy, cells were 
cultured in CDT; CDT plus Tam; or CDT plus the antiestrogen 
ICI 182780 (ICI). Following treatment with these modalities, cells 
were labeled with BrdU to determine the influence of each agent 
on cell-cycle progression and the corresponding influence of RB 
knockdown on this response (Figure 4B; data from multiple clones 
are presented in Supplemental Figure 3). These experiments were 
recapitulated in the polyclonal populations of T47D and Zr-75-1 
donor and siRb88 cells (Figure 4C). All conditions limiting estrogen 
function elicited cell-cycle inhibition in cells harboring functional 
RB. However, this action of each agent was significantly reduced 
by the depletion of RB. These results indicate that RB-deficient 
cells are able to partially bypass the cell-cycle blockade elicited by 
antiestrogen therapy. To elucidate the long-term growth effects of 
these therapies, cell proliferation assays were performed over 9 days. 
RB-proficient and -deficient MCF7 cells were seeded at equal densi-
ties and cultured in CDT/Tam (Figure 4D). As previously described, 
control MCF7 cells did not exhibit cell proliferation (2). However, 
cells lacking RB were able to continue to proliferate in this hor-
mone-deprived environment. Similar results were evident in the 
same experiments with both T47D and Zr-75-1 RB-proficient and 
-deficient polyclonal pools (Figure 4E). To assess the role of RB in 
the therapeutic response of MCF7 cells in vivo, the xenograft model 
was again employed. Upon the attainment of tumors of approxi-
mately 100–120 mm3, mice were deprived of estrogen and treated 
with Tam. Tumor measurements taken at 4-day intervals demon-
strated that RB-proficient tumors respond to Tam by regressing to 
nearly immeasurable sizes (Figure 4F). However, the RB-deficient 
counterparts did not regress and, indeed, increased in size from 
approximately 110 mm3 to 150 mm3 in the presence of Tam. All 
tumors were weighed upon excision, and RB-deficient tumors were 
more than 3-fold heavier than control tumors following Tam ther-
apy (Figure 4G). Together, these data demonstrate that hormone 
deprivation therapy is compromised in breast cancers harboring 
functional inactivation of the RB pathway.
RB target gene upregulation is a prognostic indicator in human breast 
cancers. RB performs a myriad of functions, the most well under-
stood being repression of the E2F family of transcription factors. 
To determine the specific influence of the E2F axis on bypassing 
therapy, an activator E2F was overexpressed in wild-type MCF7 
cells. Specifically, cells were infected either with an adenovirus 
encoding E2F3 (Ad-E2F3) or a control virus (Ad-LacZ) and were 
harvested 3 days after infection for immunoblot analysis of levels 
of known RB-E2F targets (Figure 5A). Relative to control (lane 1), 
the Ad-E2F3–infected MCF7 cells (lane 2) exhibited significantly 
increased protein levels of E2F target genes, including PCNA and 
MCM7. As expected, no changes were detected in RB levels, and 
CDK4 served as a loading control. In order to assess the response 
to therapeutic intervention, 3 days after infection Ad-E2F3– or 
Ad-LacZ–infected MCF7 cells were separated into 2 major treat-
ment groups: hormone therapy and DNA damage therapy. The 
estrogen ablation group was then cultured in the absence of estro-
gen and in the presence of Tam or ICI as described above. Alter-
natively, the cells in the DNA damage therapy group were treated 
with 16 μM CDDP for 18 hours prior to washing or treatment with 
5 Gy IR. Cells from both therapy groups were BrdU labeled, and 
the replicative fraction of treated cells was determined with respect 
to untreated control cells (Figure 5B). Cells overexpressing E2F3 
exhibited significantly reduced levels of cell-cycle arrest in each 
therapeutic condition as compared with the control infected cells. 
This result indicates that the ability of RB-deficient breast cancer 
cells to bypass therapeutic cell-cycle arrest is due to unrestrained 
E2F activity, suggesting that RB/E2F-regulated target gene expres-
sion is an important marker of therapeutic response.
To determine the significance of RB/E2F target gene expression 
in human breast cancer, we analyzed a tumor microarray data set 
representing 60 breast cancer patients with ER-positive disease 
who were treated with Tam monotherapy. The tumor specimens 
in all cases had been both micro- and macrodissected (22). A gene 
expression signature of 59 genes that are deregulated with RB 
genetic loss and repressed upon RB activation was utilized to clus-
ter this 120-point data set (60 tumors, macro- and microdissected) 
and is displayed as a condition tree (Figure 6A). This map shows 
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Figure 4
RB is necessary for sensitivity to antiestrogen therapy and long-term growth arrest. (A) Lysates from wild-type MCF7, T47D, and Zr-75-1 cells 
were immunoblotted for the expression levels of RB, RB phospho-Ser780, cyclin D1, and p16INK4a. Lamin B served as a loading control, while 
lysates from U2OS and SaOS2 cells were included as controls for RB and p16INK4a expression, respectively. (B) MCF7 donor 1 and siRb28 
clones were cultured in media containing FBS, CDT, CDT/Tam, or CDT/ICI for 3 days and were BrdU labeled for the final 10 hours of culture. 
Cells were then fixed, and BrdU immunofluorescence was performed and scored. A 2-tailed Student’s t test assuming unequal variances was 
utilized to determine significance. (C) T47D (left) and Zr-75-1 (right) donor and siRb88 cells were cultured, BrdU labeled, and scored as described 
for B. Statistical tests were performed as described for B. (D) MCF7 donor 1 or siRb28 cells were seeded at 3 × 105, and cell growth assays 
were performed for 9 days while cells were cultured in CDT/Tam and counted every 3 days. (E) T47D (left) and Zr-75-1 (right) donor and siRb88 
cells were seeded at 3 × 105, and cell growth assays were performed as described for D. (F) When xenograft tumors (as in Figure 3E) reached 
100–120 mm3, mice were treated with Tam (E2 pellet was removed and Tam pellet was added). Tumor size of the Tam-treated animals was 
monitored by calipers. (G) Final tumor weights of all tumors represented in F upon excision.
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3 major regions of gene coregulation: low, medium, and high RB 
target gene expression (blue, yellow, and red regions, respectively). 
This clustering placed the macro- and microdissected samples 
from 59 of 60 patients in the same gene expression groups, with 
only 1 tumor signature split between the high and medium gene 
expression groups on the condition tree.
First, correlations of the RB gene signature with known effectors 
of breast cancer growth or development were assessed for relevance 
to the RB signature. Only 3 tumors within the cohort exhibited 
HER2/neu positivity (labeled as a, b, and c in Figure 6A), thus indi-
cating that HER2 status does not underlie the observed changes 
in gene expression pattern. Relative expression of Rb and p16ink4a 
was also examined, and mRNA levels showed no significant altera-
tion across the tumor specimens. This result is not unexpected, 
as relative Rb and p16ink4a mRNA levels are typically unaltered 
even in tumors with loss of heterozygosity at the RB locus and/or 
that score histologically negative for RB expression (e.g., in small 
cell lung carcinoma; data not shown) (23). These observations are 
consistent with the established observations that RB inactivation 
is frequently associated with regulation of protein function rather 
than loss of the RB gene itself in breast cancer. Since one suggested 
mechanism for loss of RB function is attributed to excessive G1 
cyclin/CDK activity, relative G1 cyclin mRNA levels were analyzed 
in the cohort. As shown, cyclin D1 levels did show a differential 
expression pattern, wherein a large number of tumors (43%) 
showed elevations in cyclin D1 mRNA production. However, cyclin 
D1 status did not correlate with the RB gene expression signature, 
thus indicating that the major mechanism of RB inactivation in 
this tumor cohort is unlikely to result from enhanced cyclin D1 
gene expression. Moreover, these data indicate that the RB signa-
ture is not a general consequence of cell-cycle aberrations. Cyclin E 
mRNA levels did show an inverse relationship with functional RB, 
consistent with existing literature (24), and correlated with the 
high RB gene expression group. Together, these data indicate that 
the RB-deficient signature is specific and likely arises from func-
tional inactivation of the tumor suppressor action.
To address the importance of the RB deficiency 
signature on therapeutic response, patient out-
come was examined. Recurrence data revealed that 
the patients in the “high” target gene group have an 
increased incidence of cancer recurrence (65%) rela-
tive to the patients in the other 2 groups (38%). The 
increased levels of RB/E2F target genes in this high 
group would suggest that these tumors are func-
tionally disrupted for the RB pathway, and their 
poor response to Tam therapy would correspond 
with data described herein. The average expression 
levels of these 59 RB target genes in each of the 3 
groups are quantitatively displayed as a box plot 
to reveal an approximate 3-fold increase in gene 
expression from the low to the high group (Figure 
6B). For each patient, the time to disease recurrence 
is known, and a recurrence-free survival curve was 
generated (Figure 6C). Patients responded poorly 
to Tam in the high expression group, wherein the 
median recurrence-free survival was 62.5 months, 
and only 35% remained recurrence free. In contrast, 
patients in the low/medium RB target gene expres-
sion groups had an improved prognosis on Tam 
therapy, with greater than 62% remaining disease 
free. Thus, compromised control of the RB/E2F axis is associated 
with poor response to Tam in human breast cancer.
Discussion
The RB tumor suppressor is functionally inactivated in a large 
fraction of human cancers (25). Traditionally, this event is asso-
ciated with the genesis of cancer as opposed to the effect on the 
therapeutic response of a given tumor type. Here we evaluated 
the influence of RB deficiency in the context of established breast 
cancer cells and found that while attenuation of RB function did 
accelerate cellular and tumorigenic proliferation, it also had a 
profound influence on the response to key therapeutic modalities 
utilized in the treatment of breast cancer.
It is widely held that RB functions as a negative regulator 
of cell-cycle progression that is targeted at high frequency in 
human cancers by a myriad of mechanisms. The frequency of 
this event has led to the hypothesis that most cancers function-
ally inactivate RB during tumor progression (25–27). Such a 
model would suggest that although the RB protein is expressed 
in many tumor types, it is functionally inert due to upstream 
deregulation of RB phosphorylation. In this work, we investi-
gated the influence of RB deficiency on several breast cancer 
cell lines. We found that knockdown of RB led to the enhanced 
expression of E2F target genes, suggesting that the RB protein 
present in MCF7 cells is at least partially functional. Subsequent 
analyses of cell-cycle progression and cellular proliferation indi-
cated that, similar to what is observed in primary cells, knock-
down of RB induces a modest proliferative advantage in MCF7, 
T47D, and Zr-75-1 cells (28). Strikingly, in MCF7 cells, RB defi-
ciency also facilitated tumorigenic proliferation. Thus, while 
many mechanisms may attenuate the RB pathway sufficiently 
to promote tumorigenesis, many tumor lines retain sufficient 
RB activity to activate checkpoints when provoked, such that 
complete deficiency of RB can further enhance proliferation and 
alter tumor cell behavior.
Figure 5
E2F3 overexpression in MCF7 cells allows bypass of antimitogenic checkpoints. (A) 
MCF7 cells infected with adenoviral vectors encoding either lacZ or E2F3 were har-
vested 3 days after infection, lysed, separated by SDS-PAGE, and immunoblotted 
for determination of E2F3, RB, MCM7, and PCNA expression levels. Cdk4 served as 
a loading control. (B) The adenovirus-infected cells represented in A were cultured 
in media containing FBS, CDT, CDT/Tam, or CDT/ICI for 3 days or were treated as 
described above with 16 μM CDDP or 5 Gy IR prior to BrdU labeling for 10 hours. Cells 
were then fixed, and BrdU immunofluorescence and scoring were performed.
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Breast cancer, like all cancers, is a heterogeneous disease. In the case 
of ER-positive disease, Tam or similar antiestrogenic compounds 
are utilized to treat the cancer. However, many ER-positive patients 
develop resistance to antiestrogen therapy, and an alternative line 
of therapy such as either radiation or chemotherapy is required. It 
has been found in primary cells that the RB/E2F pathway plays an 
important role in mediating cell-cycle inhibition following expo-
sure to such agents (29, 30). In several breast cancer cell lines, we 
Figure 6
RB/E2F downstream target deregulation correlates with poor prognosis in human breast cancers treated with Tam monotherapy. (A) Gene 
expression data from 60 ER-positive human breast tumors that were both micro- and macrodissected were analyzed for RB/E2F target gene 
expression using GeneSpring. The expression patterns of 59 known RB/E2F target genes and the expression levels of Rb, p16, cyclin D1, and 
cyclin E are displayed in a condition tree for each of the 2 tissue samples from each patient (120 samples). The average RB/E2F target gene 
expression levels of all 59 genes were categorized into 3 groups: low, medium, and high. Three HER2/neu-positive tumors (a, b, and c) were 
present in this tumor set. (B) The RB/E2F target gene expression levels in each group represented in C were averaged and displayed as a box-
and-whisker plot. A 2-tailed Student’s t test assuming unequal variances was utilized to determine significance (P = 7.2 × 10–12 low/medium; 
P = 1.3 × 10–14 medium/high). (C) The survival data for each of the 60 patients from the low/medium and high gene expression groups repre-
sented in C was compiled into a disease-free survival curve. Statistical tests were performed as described for B.
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observed a similar dependence on RB/E2F function, as either the 
knockdown of RB or overexpression of E2F3 (MCF7 cells) enabled 
bypass of the DNA damage checkpoint. Strikingly, this loss of 
checkpoint function increased the sensitivity of RB-deficient MCF7 
cells or tumors to IR and CDDP, respectively. These findings are 
in agreement with prior studies in primary murine cells, where RB 
deficiency was found to enhance susceptibility to death following 
DNA damage (31, 32), which was most likely due to deregulation 
of cell-cycle and proapoptotic genes (33, 34). Thus, aberrations in 
RB, while uncoupling cell-cycle responses, lead to enhanced sensitiv-
ity to cytotoxic therapeutics that function by damaging DNA. This 
is clinically important for patients harboring either ER-negative or 
ER-positive Tam-resistant tumors. In addition, disruptions in the 
p53 pathway are known to occur in 20%–40% of breast cancers, 
although most frequently in ER-negative cases (35). Therefore, the 
influence of p53 function on DNA damage checkpoint response 
and sensitivity in MCF7 models was examined, and these analyses 
showed that while p53 does impact the DNA damage checkpoint, 
there was only a marginal effect on long-term sensitivity, as sug-
gested in the literature (36). These data indicate that RB function 
modifies therapeutic response even in the absence of p53.
First-line therapy for ER-positive breast cancer exploits the estro-
gen dependence of these cells. Treatment of estrogen-sensitive ER-
positive tumors with estrogen antagonists results in inhibition of 
tumor growth (37) and corresponding tumor regression. However, 
up to 50% of ER-positive tumors fail to respond to such therapeu-
tics (38). Here we determined the influence of compromising the 
RB/E2F pathway on response to estrogen antagonists. Cells with a 
disruption in this pathway failed to undergo cell-cycle inhibition 
following hormone therapy. However, unlike the situation with 
DNA-damaging agents, the RB-deficient breast cancer cells contin-
ued to proliferate in the presence of Tam. As a result, RB-deficient 
tumors continued to progress in the presence of Tam and thus 
failed therapy. However, RB deficiency only partially bypassed the 
requirement for estrogen. This finding is likely attributed to the 
complexity of estrogen signaling pathways, which cannot be fully 
recapitulated by RB deficiency (39, 40). Such a supposition is sup-
ported by partial bypass that is observed with overexpression of 
HER2/neu (41). Interestingly, although p53-deficient MCF7 cells 
were able to bypass the DNA damage checkpoint, the same was 
not evident following hormone ablation therapy (Supplemental 
Figure 4E). These data, combined with the observation that MCF7, 
T47D, and Zr-75-1 cells are all p16INK4a deficient (19) yet dis-
play resistance to hormone therapy upon RB knockdown, suggest 
that the influence of RB on the response to antiestrogen therapy is 
not effectively recapitulated by other tumor suppressor pathways. 
Together, these findings have significant clinical impact, since the 
majority of tumors that initially respond to Tam eventually devel-
op cellular resistance (42).
The involvement of RB function in breast cancer therapy has not 
previously been examined. In human disease, disruption of the RB 
pathway occurs with relatively high frequency (>80%) (13, 17) and 
is often associated with poor prognosis. Since RB function can be 
disrupted via mechanisms that do not directly target the protein 
(e.g., point mutations) and deregulated E2F activity could similarly 
bypass Tam, we reasoned that analyses of RB target genes could 
result in an important determinant of Tam response. These RB 
target genes have been defined based on RB genetic loss and induc-
tion of RB function in cells. As expected, this “signature” is largely 
consistent with genes that are also regulated by the E2F family of 
transcription factors. Supporting such analyses, high levels of the 
RB/E2F targets cyclin A and cyclin E have been reported to corre-
late with Tam resistance (43, 44). Furthermore, we found that high 
expression of RB target genes was associated with poor response to 
Tam in the context of monotherapy. Therefore, these clinical data 
indicate that disruption of the RB/E2F pathway plays a role in the 
progression of breast tumors to antiestrogen resistance. It could be 
reasoned that upregulation of RB/E2F targets, many of which are 
cell-cycle genes, could be associated with poor prognosis in general. 
However, in studies to define gene expression signatures in breast 
cancer survival, metastasis, and tumor grade, RB/E2F target genes 
have not been widely represented (45–48), except in highly specific 
subpopulations of patients (18). Interestingly, RB targets from our 
signature do consistently constitute a small subset of these gene 
lists and thus should be subject to further investigation, as they 
could contribute not only to therapeutic bypass but disease severity 
and aggressiveness. In fact, aberrations in RB have been document-
ed to correspond with ER negativity in breast cancers (16, 49, 50), 
indicating that RB functional inactivation could be a crucial step in 
the progression to advanced disease. There are a myriad of mecha-
nisms through which RB functional inactivation could occur to 
deregulate gene expression in breast cancer. Our studies suggest 
that cyclin D1 gene upregulation or protein overexpression (data 
not shown) fail to predict Tam response. This is consistent with 
several studies that have shown that cyclin D1 levels do not strin-
gently correlate with Tam resistance (51, 52). Although our studies 
are modeling immunohistochemical loss of RB, disruption of RB 
transcriptional repression can occur through additional mecha-
nisms that could also contribute to Tam resistance. For example, 
excessive cyclin E expression, expression of hyperactive (low-molec-
ular-weight) cyclin E, loss of the CDK2 inhibitor p27kip1, or loss 
of the Brm SWI/SNF ATPase have been shown to compromise RB 
function in cancer cells (44, 53, 54). The proximal influence of RB 
on target gene deregulation remains under investigation, and an 
understanding will be critical for refining application of the RB 
signature. Together, these studies strongly suggest that disruption 
of the RB/E2F axis has a deleterious influence on hormone therapy 
and could be utilized as a metric for informing therapeutic choice.
Methods
Cell lines, viral infections, and culture. The MCF7, T47D, and Zr-75-1 cell lines 
were obtained from ATCC and propagated in DMEM containing 10% FBS 
supplemented with 100 U/ml penicillin/streptomycin and 2 mM l-gluta-
mine at 37°C in air containing 5% CO2. Cells were infected with adenovirus 
encoding either E2F3 (Ad-E2F3 was a generous gift from James DeGregori, 
University of Colorado Health Sciences Center, Aurora, Colorado, USA) 
or the lacZ gene (Ad-lacZ was kindly supplied by Nancy Ratner, Cincin-
nati Children’s Hospital Medical Center) as a control. Cells were infected 
with Ad-lacZ at a multiplicity of infection of 50, at which 95% of cells were 
infected (as determined by plaque assay in 293 cells) or with 2.7 × 1011 virus 
particles/ml of Ad-E2F3 and cultured for 3 days prior to use. RB-knock-
down or control MCF7 cells were created through transfection with either 
an shRNA plasmid directed against Rb (MSCV-Rb3C; targeted sequence: 
5′-CGCATACTCCGGTTAGGACTGTTATGAA-3′) or a control plasmid 
(MSCV donor) using FuGENE Transfection Reagent (Roche Applied 
Science). Following selection with 2.5 μg/ml puromycin for 3–4 days, sta-
ble clones were isolated and characterized. Retrovirus encoding an shRB 
plasmid (MSCV-LMP Rb88; targeted sequence: 5′-GAAAGGACATGT-
GAACTTA-3′) or control plasmid (MSCV donor) were utilized to create 
RB-knockdown or control Zr-75-1 and T47D cell lines. Following selection 
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with 2.5 μg/ml puromycin for 3–4 days, polyclonal cell lines were character-
ized. MCF7 donor 1 and MCF7siRb28 cells were infected with retrovirus 
encoding LXSN or LXSN-p53dd (generously provided by Susanne Wells, 
Cincinnati Children’s Hospital Medical Center) (55), selected with 900 
μg/ml G418 for 7 days, and pooled for characterization.
To study the effect of estrogen depletion, cells were cultured for 72 hours 
in phenol red–free DMEM supplemented with 10% CDT serum with addi-
tion of 10–9 M 4-HydroxyTam (Sigma-Aldrich) or 10–6 M ICI (Tocris Biosci-
ence) where indicated. Cell growth assays were performed by trypsinizing 
cells and counting by trypan blue exclusion every 3 days.
Immunoblot analysis, immunofluorescence, and DNA damage. Cells were har-
vested by trypsinization and lysed in RIPA buffer. Equal amounts of pro-
tein, as determined by Bio-Rad DC assay, were resolved by SDS-PAGE. Spe-
cific proteins were detected by standard immunoblotting procedures using 
the following primary antibodies: p16INK4a (F-12; 1:500 dilution; Santa 
Cruz Biotechnology Inc.), cyclin D1 (H295), PCNA (pc10), cyclin E (HE12), 
cyclin A (C-19), MCM7 (141.2), E2F3 (C-18), cdk4 (H-22), lamin B (M-20), 
p21 (C-19), p53 (Ab-6; 1:500 dilution; Calbiochem; EMD Biosciences), RB 
phospho ser 780 (9307S; 1:500 dilution; Cell Signaling Technology), and 
anti-RB (G3-245; 1:100 dilution; BD Biosciences). Immunofluorescence 
staining for RB was performed on cells growing on coverslips by fixing 
them in 3.7% formaldehyde in PBS for 10 minutes. Cells were permeabi-
lized in 0.3% Triton X-100 in PBS for 20 minutes and blocked in 5% fetal 
goat serum in PBS for 1 hour. Cells were incubated in blocking solution 
with anti-RB antibody (G3-245; 1:25 dilution; BD Biosciences) for 1 hour 
at 37°C followed by PBS washing and incubation with Alexa Fluor 488–
conjugated secondary antibody (1:100; Invitrogen) and counterstained 
with DAPI (Sigma-Aldrich).
Cells treated with IR were exposed to 137Cs (dose rate: 0.67 Gy/min) at 
room temperature in tissue culture media. Culture with clinical grade 
CDDP for 18 hours was performed for all CDDP treatments. For all pro-
liferation studies, cells were labeled with BrdU for 10 hours or 5 hours 
for LXSN/LXSN-p53dd infected cells, and BrdU immunofluorescence was 
performed as previously described (56). All BrdU results are expressed as a 
percentage of untreated control cells set to 100%, unless otherwise noted.
Xenograft studies and immunohistochemistry. Five- to 8-week-old female ovari-
ectomized athymic nude mice (Harlan) were anesthetized, and an E2 pellet 
(1.7 mg/pellet, 90-day release; Innovative Research of America) or placebo 
was surgically implanted in the back. Following implantation, 200 μl of a 
PBS-and phenol red–free Matrigel matrix basement membrane (BD Biosci-
ences), solution (3:1) containing 2 × 106 cells was injected subcutaneously 
into the flank, or contralaterally where noted. Tumor volume was measured 
with calipers every 4 days using the equation V = 0.52 (width)2 × (length). In 
the therapeutic studies, when tumor volume reached 100–120 mm3, animals 
were placed into 1 of 3 therapeutic groups (each group containing at least 6 
animals): control animals retaining the estrogen pellet, antiestrogen-treated 
animals, or CDDP-treated animals. Animals in the antiestrogen treatment 
group were anesthetized, the estrogen pellet was surgically removed, and 
a Tam pellet (5 mg/pellet, 60-day release; Innovative Research of America) 
implanted. The CDDP-treated animals received 5 mg/kg CDDP injected i.p. 
on a q4dx5 schedule (every 4 days for 5 courses). All animals were injected 
i.p. with 150 mg/kg BrdU (Sigma-Aldrich) 1 hour prior to euthanization. 
Xenograft tumors were weighed and fixed in 10% neutral buffered formalin, 
paraffin embedded, and cut into 5-μm sections. For immunohistochemical 
staining, sections were deparaffinized in xylene and rehydrated through a 
graded series of ethanol/water solutions. A BrdU detection kit (Zymed) was 
utilized as recommended by the manufacturer. BrdU incorporation was 
scored in a blinded manner, and at least 500 cells per section were counted 
from several random fields. All animal experimentation was conducted in 
accordance with the NIH Guide for Care and Use of Laboratory Animals 
and was approved by the University of Cincinnati Institutional Animal Care 
and Use Committee.
Microarray analysis. Microarray data (series GSE1378 and GSE1379) from 
X.J. Ma et al. (22) were obtained from the National Center for Biotechnol-
ogy Information Gene Expression Omnibus (GEO) website (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL1223) and manipulated 
using GeneSpring GX software (version 7.2) (Agilent Technologies). For 
each series, the raw data was obtained from GEO as log2 of normalized 
Cy5/Cy3 ratio, where tumor sample RNA and human universal refer-
ence RNA were labeled with Cy5 and Cy3, respectively. The raw data were 
transformed from log2 to linear values followed by per-gene median nor-
malization in GeneSpring. A 120-sample experiment was then created by 
combining the normalized data of the 2 series (60 tumors, macro- and 
microdissected). The expression levels of 59 RB target genes analyzed were 
derived from analyses of RB loss or gain of function in model systems. 
To identify the effect of RB loss on gene expression, Affymetrix gene chip 
analyses were performed using primary murine fibroblasts, wherein the 
Rb gene is chronically or acutely inactivated. The gain of function studies 
have been previously published (57). The expression levels of these 59 genes 
were analyzed in the combined experiment of 120 breast cancer specimens. 
Initially, the genes were clustered based on standard correlation as the 
similarity measurement. Subsequently, a condition tree based on distance 
correlation was created to order the tumor specimens.
The low, medium, and high expression groups were significantly dis-
tinct based on gene expression. Specifically, using a 2-tailed Welch’s t test, 
the high group was statistically distinct from the low and medium groups 
(P = 2.3 × 10–19 and P = 1.3 ×10–14), and the medium group was statistically 
distinct from the low group (P = 7.2 × 10–12). For Kaplan-Meier analysis, 
statistical calculations were performed using GraphPad Prism 4.0 soft-
ware, and the P value presented (P = 0.008) was based on a log-rank Man-
tel-Haenzel test (Figure 6). All other results were analyzed for statistical 
significance using the 2-tailed Student’s t test. For all analyses, P < 0.05 
was considered significant.
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